Study shows prebiotic Bimuno (Clasado) shows some benefits to Gastrointestinal health

A randomized, placebo-controlled study of the prebiotic Bimuno, from Clasado, shows evidence of benefit in patients at risk of reduced Gastrointestinal health. A total of 45 overweight adults (body mass index > 25 kg/m2) with at least 3 risk factors for Metabolic Syndrome were followed for 28 weeks. During the first 12 weeks, volunteers were randomly assigned to consume either 5.5 grams of an inactive placebo (maltodextrin) daily or the same amount of Bimuno-GOS a mixture of oligosaccharides comprised mainly of galactose subunits (the sugar found mainly in milk).

The study demonstrated that Bimuno - GOS positively affected the gut microbiota by increasing the number of positive bifidobacteria, whilst reducing more negative bacteria. Positive effects were seen as early as 6 weeks. There was also a positive effect on immune responses by increasing faecal sIgA (marker of mucosal immunity), and decreasing calprotectin and CRP (markers of inflammation). Additionally insulin, total cholesterol, triglycerides and TC/HDL ratio (markers of metabolic syndrome) was reduced. The results will be published in the March 2013 issue of The Journal of Nutrition.

For more information visit www.bimuno.com.